Nitric Acid

Nitric Acid

SCHEMBL7125664

O.O.O.O.O.O.O.O.O=[N+]([O-])O.[AlH3]

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.80
CA5B Q9Y2D0 1/20 0.80
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 3/20 0.33
TSHR P16473 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
HPGD P15428 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitric Acid SCHEMBL2466156 1.00 CA5A (0.80) CA5ACA5BMEN1KMT2AALDH1A1
Nitric Acid SCHEMBL10339100 1.00
Nitric Acid SCHEMBL218219 1.00
Nitric Acid SCHEMBL7126708 1.00
Nitric Acid SCHEMBL94578 1.00 CA5A (0.80) CA5ACA5BMEN1KMT2AALDH1A1
Nitric Acid SCHEMBL9162752 1.00
Nitric Acid SCHEMBL4014809 1.00 CA5A (0.80) CA5ACA5BMEN1KMT2AALDH1A1
Nitric Acid SCHEMBL407617 1.00 CA5A (0.80) CA5ACA5BMEN1KMT2AALDH1A1
Nitric Acid SCHEMBL8982116 0.95
Nitric Acid SCHEMBL8982097 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11631565-B2 Thermal fuse SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (US) 2023-04-18 US disclosed
US-20220165529-A1 Thermal Fuse CITIBANK, N.A., AS COLLATERAL AGENT 2022-05-26 US disclosed
CN-112011314-A Composite phase-change material for hot water supply heat accumulator and preparation method thereof 河南百川畅银环保能源股份有限公司 2020-12-01 CN disclosed
CN-109852392-B Composition for repairing contaminated soil of relocation site of electroplating enterprise and application thereof 中国科学院南京土壤研究所 2020-08-25 CN disclosed
EP-2940004-B1 METHOD FOR PRODUCING OXIME SUMITOMO CHEMICAL CO (JP) 2017-09-13 EP disclosed
US-9533944-B2 Method for producing oxime SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-01-03 US disclosed
US-20150353478-A1 METHOD FOR PRODUCING OXIME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-12-10 US disclosed
EP-2940004-A1 METHOD FOR PRODUCING OXIME Sumitomo Chemical Company Limited (JP) 2015-11-04 EP disclosed
US-6670037-B1 Coating agent consisting of delta-alumina or pseudoboehmite dispersed and aluminum nitrate nonahydrate dissolved in aqueous dispersing medium, and binder TAIHO INDUSTRIES CO., LTD. (JP) 2003-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353478-A1 METHOD FOR PRODUCING OXIME HAO2, HMOX2, OXGR1 CA5A 452/4885CA5B 417/4885MEN1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.